The NCI-H292 cell line was established from the lymph node metastasis lung cells derived from a female patient suffering from mucoepidermoid pulmonary carcinoma (lung cancer). The cells exhibit an epithelial morphology, test negative for L-DOPA decarboxylase and ultimately demonstrate similar characteristics as non-carcinogenic cells do. The NCI-H292 cells have shown susceptibility to the Hepatitis B virus, making it a useful biomedical research model. Altogen Biosystems manufactures a high efficiency transfection reagent to further examine the properties of the NCI-H292 cell line for lung cancer treatments. Transfection Reagent for NCI-H292 Cells (Lung Carcinoma Cells, CRL-1848)